Dan Shea : Yeah, you said a lot of what I would say. I think I guess the thing that comes to mind is just sort of this notion of business planning as what we’re talking about, and that’s the core of what this is all about. And so when you’re planning for a business, there’s always a treasury person in the room who is probably a bit of the skunk of the lawn party, because there’s a motivation on one side to run the SaaS as fast as possible. But of course, if you’re not bringing in and some of the revenues that were, you know that were pretty persistent before, and we were getting upfront revenue on perpetual sales, we have certain customers that probably are never going to go to SaaS, maybe they will. You know the OEMs overseas, I think there just needs to be a balance between the pace to subscription and keeping some of the perpetual for a while, and then as long as you have the right runway to – that is cash.
As long as you have enough cash to kind of hold yourself out there and just take your time and we’ll get the cloud completed at some point here in the near term, and it will start to change the whole dynamic of how the business planning evolves. But in the near term, there needs to be a balance between I guess the person wearing the treasury hat and the people who want to go to those subscription as fast as possible. Hope that makes sense.
Francois Brisebois: Yeah, that’s it from me. Thank you.
Dana Brown: Thanks.
Operator: Thank you. Your next question is coming from Frank Takkinen from Lake Street Capital Market. Your line is live.
Frank Takkinen: Hey! Thanks for taking my questions. I wanted to start with one for you Dana on some of your past experiences. I was just curious if you could elaborate on how you may elect to leverage some of that experience and some of those previous relationships into patient advocacy programs or anything of that nature that could help in better promoting ProFound.
Dana Brown: Yes, so I’ll speak about Komen in particular. So I know a lot of the work we did at Komen was focused on ensuring people were aware of their risk, right. In fact we ran campaigns that were Know Your History, Know Your Risk. A lot of the ways in which we were able to help people determine their risk were very traditional models, right; family health history, looking at other gene indicators or markers. I would say it was felt a little bit more like a survey right, or kind of a Q& A kind of approach, and then looking at just kind of correlating common factors. So the other important thing about Komen is, you’re looking at an organization that’s mobilizing, 2.5 million women on an annual basis and so they are also working with large corporate partners with women’s health initiative.
So companies like Salesforce or Disney, you know kind of a whole spectrum. So I think from iCAD’s perspective, you know we would be best served by leveraging and going direct to patient through organizations like a Komen, like a BCRF, which is Breast Cancer Research Foundation, like a Health In Her HUE, like American Cancer Society. Because those organizations are looking for additional programs and tools right, that they can create, you know make sure that their patient base is aware of and then provide ways for them to access it. Most of the, I’ll call it cancer advocacy organizations also have a lot of financial aid programs. So they help women get access to the care they need right, to screenings, especially if for example they may not have the right health benefits right, so they maybe the under insured or the non-insured.
So there are ways in which we could work with them to ensure they get access right to readings, the kind that you know our products right, the ProFound suite can offer. So I’m excited about it, because I think that maybe there’s just kind of a bit of a gap in knowledge about each other and how we could help each other, and I put those kinds of programs together in place at Komen. So I think it’s going to be a natural opportunity for iCAD to leverage.
Frank Takkinen: Okay, that’s good color. And then just for my second one, I’m just curious if you could give an update on the competitive landscape. Anything out there that’s new or different. I mean previous assumption was iCAD had a pretty good lead on everybody, and with it continuously ingesting more data, it should continue to protect that lead. But its growth has slowed a little bit and was curious if that dynamic has changed and some other players have had the opportunity to improve their positioning.
